Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

3.32
-0.0700-2.06%
Post-market: 3.390.0700+2.11%19:49 EDT
Volume:947.27K
Turnover:3.16M
Market Cap:143.74M
PE:-4.28
High:3.42
Open:3.38
Low:3.31
Close:3.39
52wk High:5.06
52wk Low:1.62
Shares:43.30M
Float Shares:37.42M
Volume Ratio:1.10
T/O Rate:2.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7754
EPS(LYR):-1.3374
ROE:-682.61%
ROA:-63.99%
PB:-845.54
PE(LYR):-2.48

Loading ...

NRX Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jun 03

NRx partner Emobot reports pooled clinical validation of EMOCARE depression monitoring tool at ASCP 2026

Reuters
·
May 28

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

GlobeNewswire
·
May 27

NRX Pharmaceuticals (Nasdaq:Nrxp) Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 18

Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 18

NRX Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M

Benzinga Earnings
·
May 16

NRx Pharma Q1 FY26 net loss narrows to $1.43 million; revenue turns to $1.07 million

Reuters
·
May 16

NRX Pharmaceuticals Inc expected to post earnings of 29 cents a share - Earnings Preview

Reuters
·
May 15

NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga Earnings
·
May 15

NRx Pharmaceuticals to report Q1 2026 results, host conference call

Reuters
·
May 14

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) to Report First Quarter 2026 Financial Results and Provide Corporate Update

THOMSON REUTERS
·
May 14

NRX Pharmaceuticals Inc expected to post earnings of 29 cents a share - Earnings Preview

Reuters
·
May 11

NRx Pharmaceuticals wins FDA clearance to start NRX-101 depression, suicidality trial

Reuters
·
May 07

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 06

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

GlobeNewswire
·
May 05

NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Apr 27

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 23

NRX Pharmaceuticals Inc - Receives Positive FDA Discipline Review Letter Requesting Only Minor Administrative Changes

THOMSON REUTERS
·
Apr 22

NRX Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

THOMSON REUTERS
·
Apr 22